RYI Stock Overview
A clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Viracta Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.72 |
| 52 Week High | US$1.49 |
| 52 Week Low | US$0.24 |
| Beta | 0.44 |
| 1 Month Change | -11.59% |
| 3 Month Change | 11.54% |
| 1 Year Change | -51.34% |
| 3 Year Change | -92.06% |
| 5 Year Change | n/a |
| Change since IPO | -83.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| RYI | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -4.6% | 0.4% | -1.7% |
| 1Y | -51.3% | -24.6% | 6.2% |
Return vs Industry: RYI underperformed the German Biotechs industry which returned -24.6% over the past year.
Return vs Market: RYI underperformed the German Market which returned 6.2% over the past year.
Price Volatility
| RYI volatility | |
|---|---|
| RYI Average Weekly Movement | 15.8% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.6% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: RYI's share price has been volatile over the past 3 months.
Volatility Over Time: RYI's weekly volatility has decreased from 26% to 16% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 40 | Mark Rothera | www.viracta.com |
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company’s Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
Viracta Therapeutics, Inc. Fundamentals Summary
| RYI fundamental statistics | |
|---|---|
| Market cap | €27.56m |
| Earnings (TTM) | -€44.25m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs RYI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RYI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$47.99m |
| Earnings | -US$47.99m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 168.6% |
How did RYI perform over the long term?
See historical performance and comparison